While MUC1, MUC4, MUC15, MUC16, MUC17, and MUC21 are all potential candidate biomarkers for glioma, the extensive research on MUC1 and the current clinical application of MUC16 in ovarian cancer highlights their promise as therapeutics for glioma. This evidence concerns the gene MUC1 and ovarian carcinoma.